Electrophysiology
Treatment strategies for persistent atrial fibrillation
Also called persistent AFib, long-standing persistent AF
Sources: updated Oct 1, 2026
CABANA and EARLY-AF
Cardiology Trials Journal Club — Tue, Sep 15, 10:00 AM EDT
AFFIRM and RACE
Cardiology Trials Journal Club — Tue, Sep 8, 10:00 AM EDT
SAFE-T and RACE II
Cardiology Trials Journal Club — Tue, Sep 1, 10:00 AM EDT
ANDROMEDA, ATHENA and PALLAS
Cardiology Trials Journal Club — Tue, Aug 25, 10:00 AM EDT
#bruinhearts VA Journal Club--NEMESIS PFA
UCLA #bruinhearts Journal Club Section — Fri, Aug 21, 11:00 AM EDT — 2 attended
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
“CABANA failed to demonstrate a statistically significant reduction in primary composite cardiovascular outcomes for catheter ablation compared with medical therapy.”
“For older, minimally symptomatic atrial fibrillation patients, rhythm control does not improve survival compared with rate control and requires continued anticoagulation.”
“The SAFE-T trial demonstrated amiodarone's superiority over sotalol for rhythm maintenance, but intention-to-treat quality-of-life benefits remained neutral.”